FutureCeuticals Inc. announced publication of the results of a successful human clinical study on FruiteX-B® Calcium Fructoborate, a patented mineral complex, in the Journal of Aging Research and Clinical Practice.
The double-blind, placebo-controlled study examined the effects of FruiteX-B with a combination of glucosamine and chondroitin versus glucosamine and chondroitin alone on joint health and flexibility. Outcome measures included the widely used WOMAC and McGill questionnaires, standard indices of joint and flex comfort.
Over 14 days, subjects in the FruiteX-B, glucosamine, and chondroitin group experienced a 24 percent improvement in WOMAC scores and a 25 percent improvement in McGill scores. Subjects taking the glucosamine/chondroitin combination alone did not experience any significant improvements. Statistics were independently reviewed by the Department of Statistics, School of Information and Computer Science, University of California at Irvine.
"This study shows that in the context of the widely used combination of glucosamine and chondroitin, FruiteX-B continues to provide the significant benefits for joint health documented in previous research on this remarkable mineral complex," said Hartley Pond, the company's vice president of sales. "The results in the FruiteX-B, glucosamine, and chondroitin group align with previous studies published earlier this year and in 2012. In all instances, FruiteX-B delivered significant, fast-acting improvement that people feel."
"With an advantageous serving size and price, FruiteX-B is capable of delivering the now requisite "take-it, feel-it" experience while enhancing the sustained, slower-onset, long-term relief afforded by the stand-by ingredients," Pond added.